
News|Articles|July 1, 2004
New molecular entity: Trospium
The parasympatholytic action of trospium reduces the tonus of smooth muscle in the bladder by antagonizing the effect of acetylcholine on muscarinic receptors. Trospium was approved on May 28, 2004, for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Don’t let ‘sleepmaxxing’ keep you up at night: Results from the 2025 American Academy of Sleep Medicine survey on sleep tracking
2
What UnitedHealth Group’s earnings call reveals about managed care trends
3
3 insights from the third set of drugs for Medicare price negotiations
4
Slight Medicare Advantage payment increase sparks debate over risk adjustment
5




























